{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:46:01Z","timestamp":1786977961729,"version":"build-2736575974"},"reference-count":38,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,7,30]],"date-time":"2013-07-30T00:00:00Z","timestamp":1375142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pain"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Spironolactone, a commonly used mineralocorticoid receptor antagonist, has been reported to potentiate the effect of morphine in the rat. The aim of this study was to investigate the effects of spironolactone on morphine antinociception and tissue distribution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The effects of spironolactone on acute morphine\u2010induced antinociception, induction of morphine tolerance and established morphine tolerance were studied with tail\u2010flick and hot plate tests in male\n                      <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>\n                      prague\u2010\n                      <jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>\n                      awley rats. Serum, brain, and liver morphine and its metabolite concentrations were quantified using high\u2010pressure liquid chromatography\u2010tandem mass spectrometry. Spironolactone was also administered with the peripherally acting,\n                      <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>\n                      \u2010glycoprotein (\n                      <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>\n                      \u2010gp) substrate loperamide to test whether spironolactone allows loperamide to pass the blood\u2013brain barrier.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Spironolactone (50\u2009mg\/kg, i.p.) had no antinociceptive effects of its own, but it enhanced the antinociceptive effect of morphine in both thermal tests. Two doses of spironolactone enhanced the maximum possible effect (\n                      <jats:styled-content style=\"fixed-case\">MPE<\/jats:styled-content>\n                      ) from 19.5% to 100% in the hot plate test 90\u2009min after administration of 4\u2009mg\/kg morphine. Morphine concentrations in the brain were increased fourfold at 90\u2009min by spironolactone. Spironolactone did not inhibit the formation of morphine\u20103\u2010glucuronide. Acute spironolactone restored morphine antinociception in morphine\u2010tolerant rats but did not inhibit the development of tolerance. The peripherally restricted opioid, loperamide (10\u2009mg\/kg), had no antinociceptive effects when administered alone, but co\u2010administration with spironolactone produced a 40%\n                      <jats:styled-content style=\"fixed-case\">MPE<\/jats:styled-content>\n                      in the hot plate test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Spironolactone has no antinociceptive effects in thermal models of pain, but it enhances the antinociceptive effects of morphine mainly by increasing morphine central nervous system concentrations, probably by inhibiting\n                      <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>\n                      \u2010gp.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/j.1532-2149.2013.00371.x","type":"journal-article","created":{"date-parts":[[2013,7,30]],"date-time":"2013-07-30T21:54:45Z","timestamp":1375221285000},"page":"386-395","source":"Crossref","is-referenced-by-count":11,"title":["The mineralocorticoid receptor antagonist spironolactone enhances morphine antinociception"],"prefix":"10.1002","volume":"18","author":[{"given":"T.O.","family":"Lilius","sequence":"first","affiliation":[{"name":"Institute of Biomedicine, Pharmacology University of Helsinki  Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Jokinen","sequence":"additional","affiliation":[{"name":"Institute of Biomedicine, Pharmacology University of Helsinki  Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Neuvonen","sequence":"additional","affiliation":[{"name":"Haartman Institute Department of Clinical Pharmacology University of Helsinki  Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"V\u00e4\u00e4n\u00e4nen","sequence":"additional","affiliation":[{"name":"Institute of Biomedicine, Pharmacology University of Helsinki  Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Niemi","sequence":"additional","affiliation":[{"name":"Haartman Institute Department of Clinical Pharmacology University of Helsinki  Finland"},{"name":"HUSLAB Helsinki University Central Hospital  Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.V.","family":"Rauhala","sequence":"additional","affiliation":[{"name":"Institute of Biomedicine, Pharmacology University of Helsinki  Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.","family":"Kalso","sequence":"additional","affiliation":[{"name":"Institute of Biomedicine, Pharmacology University of Helsinki  Finland"},{"name":"Department of Anaesthesia Intensive Care Medicine Emergency Medicine and Pain Medicine Pain Clinic Helsinki University Central Hospital  Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,7,30]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(02)00531-6"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(94)00552-4"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00426640"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1532-2149.2012.00148.x"},{"key":"e_1_2_9_6_1","first-page":"1","article-title":"Human UGT2B7 catalyzes morphine glucuronidation","volume":"25","author":"Coffman B.L.","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_9_7_1","first-page":"329","article-title":"Purification and properties of two rat liver phenobarbital\u2010inducible UDP\u2010glucuronosyltransferases that catalyze the glucuronidation of opioids","volume":"24","author":"Coffman B.L.","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.077792"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018943613122"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.105668"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035021"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00314854"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269216308089307"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.110.004135"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2009.08.004"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.09.019"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2003.08.011"},{"key":"e_1_2_9_18_1","first-page":"251","article-title":"Comparison of stably expressed rat UGT1.1 and UGT2B1 in the glucuronidation of opioid compounds","volume":"25","author":"King C.D.","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.032870"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1213\/01.ane.0000205751.88422.41"},{"key":"e_1_2_9_21_1","first-page":"827","article-title":"Effects of a potent and specific P\u2010glycoprotein inhibitor on the blood\u2010brain barrier distribution and antinociceptive effect of morphine in the rat","volume":"27","author":"Letrent S.P.","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2009.10.011"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e3181bdfa11"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0b013e31824c727d"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200504000-00020"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.24.403"},{"key":"e_1_2_9_27_1","first-page":"42","article-title":"A recombinant phenobarbital\u2010inducible rat liver UDP\u2010glucuronosyltransferase (UDP\u2010glucuronosyltransferase 2B1) stably expressed in V79 cells catalyzes the glucuronidation of morphine, phenols, and carboxylic acids","volume":"45","author":"Pritchard M.","year":"1994","journal-title":"Mol Pharmacol"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/0049825031000121608"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118214"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00220-0"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2008.04.015"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-0102(00)00226-1"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039897"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1136(199705)20:1<23::AID-GLIA3>3.0.CO;2-6"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.40.1.581"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702804"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2008.05647.x"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(97)00094-0"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(83)90201-4"}],"container-title":["European Journal of Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1532-2149.2013.00371.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1532-2149.2013.00371.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T04:22:41Z","timestamp":1696566161000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/j.1532-2149.2013.00371.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,30]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1002\/j.1532-2149.2013.00371.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1532-2149.2013.00371.x","archive":["Portico"],"relation":{},"ISSN":["1090-3801","1532-2149"],"issn-type":[{"value":"1090-3801","type":"print"},{"value":"1532-2149","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,30]]}}}